These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 10029600)
1. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Tomasson MH; Williams IR; Hasserjian R; Udomsakdi C; McGrath SM; Schwaller J; Druker B; Gilliland DG Blood; 1999 Mar; 93(5):1707-14. PubMed ID: 10029600 [TBL] [Abstract][Full Text] [Related]
2. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. Tomasson MH; Sternberg DW; Williams IR; Carroll M; Cain D; Aster JC; Ilaria RL; Van Etten RA; Gilliland DG J Clin Invest; 2000 Feb; 105(4):423-32. PubMed ID: 10683371 [TBL] [Abstract][Full Text] [Related]
3. TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. Wilbanks AM; Mahajan S; Frank DA; Druker BJ; Gilliland DG; Carroll M Exp Hematol; 2000 May; 28(5):584-93. PubMed ID: 10812249 [TBL] [Abstract][Full Text] [Related]
4. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Carroll M; Tomasson MH; Barker GF; Golub TR; Gilliland DG Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14845-50. PubMed ID: 8962143 [TBL] [Abstract][Full Text] [Related]
5. Evidence for a role of NF-kappaB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor beta fusion protein. Besançon F; Atfi A; Gespach C; Cayre YE; Bourgeade MF Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8081-6. PubMed ID: 9653143 [TBL] [Abstract][Full Text] [Related]
6. The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. Sternberg DW; Tomasson MH; Carroll M; Curley DP; Barker G; Caprio M; Wilbanks A; Kazlauskas A; Gilliland DG Blood; 2001 Dec; 98(12):3390-7. PubMed ID: 11719379 [TBL] [Abstract][Full Text] [Related]
7. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Ross TS; Bernard OA; Berger R; Gilliland DG Blood; 1998 Jun; 91(12):4419-26. PubMed ID: 9616134 [TBL] [Abstract][Full Text] [Related]
8. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Carroll M; Ohno-Jones S; Tamura S; Buchdunger E; Zimmermann J; Lydon NB; Gilliland DG; Druker BJ Blood; 1997 Dec; 90(12):4947-52. PubMed ID: 9389713 [TBL] [Abstract][Full Text] [Related]
9. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Golub TR; Barker GF; Lovett M; Gilliland DG Cell; 1994 Apr; 77(2):307-16. PubMed ID: 8168137 [TBL] [Abstract][Full Text] [Related]
11. The coupling of TEL/PDGFbetaR to distinct functional responses is modulated by the presence of cytokine: involvement of mitogen-activated protein kinases. Wheadon H; Welham MJ Blood; 2003 Aug; 102(4):1480-9. PubMed ID: 12714513 [TBL] [Abstract][Full Text] [Related]